title: Impact of new-generation parenteral lipid emulsions in pediatric nutrition.
abstract: Advancements in the care of premature infants and infants with severe bowel disease have occurred in which long-term use of i.v. nutrition is a cornerstone of successful therapy. Concern about the role of i.v. lipid emulsions in causing severe liver damage to high-risk infants receiving long-term i.v. nutrition has led to a variety of intervention strategies. These have had relatively limited success until the recent introduction of omega-3 (n-3) fatty acid-containing forms of lipid emulsions in place of the current omega-6 fatty acid-predominant lipid emulsions currently exclusively used in the United States. Preliminary data based on nonrandomized trials performed using compassionate-use protocols in the United States suggest very high rates of resolution of cholestasis with the use of an omega-3 fatty acid-predominant lipid emulsion. This result is supported by animal models of liver disease that demonstrate decreased liver damage when animals are provided omega-3 fatty acid-containing lipid emulsions compared with those primarily omega-6 fatty acid based. However, human trials are limited at this time and further research is needed to establish the best approach to preventing liver damage in infants receiving i.v. nutrition and the optimal dose and timing of intervention with novel lipid emulsions.
authors.affiliation: USDA Agricultural Research Service, Children's Nutrition Research Center, Department of Pediatrics, Baylor College of Medicine, Houston, TX.
authors.forename: Steven A
authors.initials: SA
authors.lastname: Abrams
mesh_terms: D000818:Animals; D002648:Child; D002657:Child Development; D053198:Child Nutrition Sciences / Q000639:trends; D002664:Child Nutritional Physiological Phenomena; D002675:Child, Preschool; D002780:Cholestasis, Intrahepatic / Q000209:etiology / Q000517:prevention & control; D003226:Congresses as Topic; D004655:Emulsions; D015525:Fatty Acids, Omega-3 / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D043371:Fatty Acids, Omega-6 / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use; D006801:Humans; D007223:Infant; D007227:Infant Nutritional Physiological Phenomena; D007231:Infant, Newborn; D007410:Intestinal Diseases / Q000628:therapy*; D057947:Parenteral Nutrition Solutions / Q000009:adverse effects / Q000737:chemistry / Q000627:therapeutic use*; D012958:Societies, Scientific; D014481:United States
chemical_list: D004655:Emulsions; D015525:Fatty Acids, Omega-3; D043371:Fatty Acids, Omega-6; D057947:Parenteral Nutrition Solutions
references.citation: Arch Pediatr Adolesc Med. 2012 May;166(5):473-8
references.pmid: 22566549
references.citation: J Nutr. 2010 Dec;140(12):2193-200
references.pmid: 20980637
references.citation: Pediatrics. 2008 Mar;121(3):e678-86
references.pmid: 18310188
references.citation: J Pediatr Surg. 2012 Jan;47(1):225-40
references.pmid: 22244423
references.citation: J Pediatr. 2013 Apr;162(4):793-798.e1
references.pmid: 23164314
references.citation: JPEN J Parenter Enteral Nutr. 2010 Jan-Feb;34(1):32-7
references.pmid: 19587385